^
Association details:
| Biomarker: | CTLA4 overexpression |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
Published date:
01/21/2022
Excerpt:
131 patients were enrolled between June 12, 2015, and Dec 6, 2018. The median age was 56 years (IQR 49–60). 58 (50%) of 117 patients had high Ki-67 (≥30%). 129 (98%, 95% CI 95–100) of 131 patients had an overall response in part A...Induction with ibrutinib–rituximab in the frontline treatment of young patients with mantle cell lymphoma is active and safe.
DOI:
https://doi.org/10.1016/S1470-2045(21)00638-0
Trial ID:
Source:
Title:
Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial
Published date:
11/06/2019
Excerpt:
...131 previously untreated young (≤65 years) pts with MCL….Pts received IR induction (part-A),...GEP was performed in 18 pts (2 PR, 16 CR on part A). Pts in PR had higher expression of HES1 while those in CR had significantly higher expression of CTLA4 and ITK genes compared with those in PR.
DOI:
https://doi.org/10.1182/blood-2019-126044
Trial ID:
